CYP2D6 rs12026: Pharmacogenetic Role and What It Means
rs12026 is a single nucleotide variant located within the human CYP2D6 locus on chromosome 22. It is routinely included on pharmacogenetic testing panels due to its association with altered cytochrome P450 enzyme activity and variable drug metabolism. While frequently screened, standalone evidence for rs12026 is considered limited, as clinical interpretations typically rely on broader multi-variant star allele haplotypes.
What each genotype means
Typical PON2 enzyme activity
This genotype represents the common form of the PON2 gene variant. Research indicates this version of the protein is associated with standard metabolic processing of certain oxidative stress markers.
This is the most common genotype observed in most global populations.
Varied PON2 enzyme activity
Carrying one copy of the G allele means you have a mix of the common and the variant form of the PON2 protein. Some studies have suggested that the G allele may be associated with altered glycemic responses in certain clinical contexts, though evidence remains limited.
This heterozygous genotype is found in a significant portion of the population, with the G allele frequency ranging between 15% and 25% globally.
Potential altered PON2 activity
This genotype results in the presence of the G allele on both copies of the gene, which leads to a specific amino acid change in the PON2 protein. Some research has explored whether this variant may exacerbate glycemic levels in individuals with non-insulin dependent diabetes mellitus, but these findings are not definitive for all populations.
This homozygous genotype is less common than the C/C or C/G genotypes but is present across diverse ancestral groups.
Genetic Architecture and Location of rs12026
rs12026 is a single nucleotide variant mapped to chromosome 22q13.2 in the coding region of the CYP2D6 gene. As documented in databases such as dbSNP and Ensembl, the CYP2D6 gene cluster contains closely related pseudogenes, making the locus structurally complex. rs12026 represents a common base substitution within this region. In clinical pharmacogenetics, individual single nucleotide polymorphisms like rs12026 rarely act entirely on their own; instead, they are evaluated as component markers of extended haplotypes—frequently termed 'star (*)' alleles. Laboratories include rs12026 in metabolic screening panels to help resolve specific CYP2D6 sub-alleles or haplotype backgrounds, ensuring that complex structural and sequence variants can be accurately cataloged across diverse individuals.
CYP2D6 Function in Drug Metabolism
The CYP2D6 gene encodes cytochrome P450 2D6, an essential hepatic microsomal enzyme that plays an outsized role in human pharmacology. Despite representing a modest percentage of total liver cytochrome P450 protein content, CYP2D6 contributes to the phase I metabolism and clearance of an estimated 20% to 25% of all clinically prescribed therapeutics. These medications encompass diverse drug classes, including selective serotonin reuptake inhibitors, tricyclic antidepressants, antipsychotics, beta-blockers, antiarrhythmics, tamoxifen, and opioid analgesics such as codeine and tramadol. Genetic variation within CYP2D6 can alter enzyme folding, stability, or catalytic efficiency, potentially categorizing patients into poor, intermediate, normal, or ultrarapid metabolizer phenotypes.
Evidence Strength and Clinical Associations
Current evidence associating rs12026 directly with solitary, independent metabolic shifts is classified as limited. While expert pharmacogenetic bodies like the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB maintain detailed clinical guidelines for CYP2D6, their recommendations focus primarily on well-defined star alleles rather than single isolated SNPs like rs12026. Studies referenced in PubMed and the GWAS Catalog evaluate rs12026 alongside other co-inherited markers to identify specific functional haplotypes. As an isolated finding, rs12026 provides insufficient predictive power to establish a patient's overall metabolizer phenotype, meaning clinical dosing guidelines cannot be directly derived from this single locus in isolation.
Ancestral Diversity and Population Patterns
According to population genomics data from gnomAD and the NCBI ALFA project, rs12026 is a polymorphic marker with a global minor allele frequency commonly spanning 0.15 to 0.25 across various major populations. Like many variants across the CYP2D6 gene cluster, its exact allele frequency fluctuates across regional ancestries, including European, African, East Asian, and admixed groups. Understanding these frequency variations is essential for clinical assay design, ensuring that pharmacogenetic testing panels do not overlook alleles that occur predominantly in underrepresented ethnic backgrounds.
Interpreting Results: What You Can and Cannot Do
Discovering your rs12026 genotype through consumer or recreational genetic testing does not provide a medical diagnosis, nor does it guarantee an altered response to specific medications. A full clinical CYP2D6 assessment requires comprehensive genotyping of star alleles, gene duplications, and non-functional hybrid alleles. You should never start, stop, or adjust the dosage of any prescribed medication based on raw direct-to-consumer genetic data. If you have concerns about drug efficacy or adverse side effects, discuss your genetic profile with a qualified physician, medical geneticist, or clinical pharmacologist.
How common is this variant?
The minor allele frequency for rs12026 typically ranges between 0.15 and 0.25 across various global ancestral groups in gnomAD and dbSNP datasets, reflecting common polymorphic variation.
Frequently asked questions
Does having the rs12026 variant mean I cannot take certain medications?
No, carrying an alternative allele at rs12026 does not automatically mean a medication will be ineffective or toxic. Clinical drug metabolism depends on your overall CYP2D6 metabolizer status, which incorporates multiple genetic variants, copy number changes, and environmental factors.
Can I change my prescription dose based on my rs12026 genotype?
Never alter, skip, or stop your medication dosages based solely on genetic test results. Always consult your prescribing physician or a clinical pharmacist, who can review accredited clinical pharmacogenetic testing before making any therapeutic adjustments.
Why is the scientific evidence for rs12026 rated as limited?
Evidence is rated as limited because rs12026 rarely acts as an independent driver of enzyme function on its own. Instead, it serves primarily as a tagging marker evaluated in conjunction with other variants to define broader CYP2D6 star allele haplotypes.
What is the difference between a single SNP like rs12026 and a CYP2D6 star allele?
A single nucleotide polymorphism (SNP) is a single base variation in your DNA sequence, while a star allele is a named haplotype representing a specific combination of multiple SNPs and structural variants inherited together that dictate enzyme activity.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs12026?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2D6
This variant is a key marker for the CYP2D6*10 allele, which results in reduced enzymatic activity and altered metabolism of various psychiatric and analgesic medications.
This variant defines the CYP2D6*4 non-functional allele, which causes impaired metabolism of numerous clinically prescribed medications including antidepressants, tamoxifen, and codeine.
Defines the CYP2D6*17 allele (p.Thr107Ile), which exhibits reduced enzyme activity towards substrates like codeine and certain antidepressants.
Defines the CYP2D6*29 variant (p.Val338Met) conferring decreased metabolic capacity, primarily observed in populations of African descent.
Promoter variant defining the CYP2D6*41 allele, associated with reduced enzyme expression and decreased metabolic capacity for various drugs.
Defines the CYP2D6*6 deletion variant (1707delT) leading to a premature stop codon and loss of enzyme function.